It is well recognized that about 30% of people with epilepsy are resistant to dual drug therapy and that selection of a second or later drug is based more on experience than empirical evidence. Drs. Fields and Marcuse of the Icahn School of Medicine discuss the current status of research and what variables will help guide antileptic selection in resistant cases.